Incidence of adverse events of concomitant immune checkpoint inhibitors and ultra hypo-fractionated radiotherapy: systematic review and meta-analysis.
Combining immunotherapy with high-dose radiation doesn't trigger worse side effects than immunotherapy alone, supporting investigation of this combination approach.
This systematic review and meta-analysis (2,057 patients, 53 trials) evaluated the safety of combining immune checkpoint inhibitors with ultra-hypofractionated radiotherapy (≥5 Gy/fraction, ≤10 fractions) and found no consistent increase in systemic toxicity compared to published ICI monotherapy rates. The manageable toxicity profile across diverse cancer types and ICI classes supports the continued investigation of this combination in clinical trials.
What the study was
- Study design
- systematic_review_meta_analysis
- Category
- sentinel
- Maturity
- Validated
- Journal
- Clinical and Translational Radiation Oncology
Why it surfaced
Safety reassurance meta-analysis for ICI + ablative RT combination; large patient population across 53 trials; directly relevant to clinical decision-making for radiotherapy-immunotherapy combinations.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.